Old Well Partners’s Janux Therapeutics JANX Stock Holding History

Old Well Partners’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,300	Closed	-$111K	–	37
2023 Q4	$111K	Hold	10,300	–	–	0.1%	42
2023 Q3	$104K	Buy	+10,300	New	+$119K	0.09%	35

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Old Well Partners's JANX Position: Q1 2024 in Review

Old Well Partners sold out of Janux Therapeutics (JANX) in Q1 2024, closing a stake of 10,300 shares — an estimated $111K sold.

Old Well Partners first reported a position in JANX in Q3 2023 and held it in 2 quarters. The position peaked at $111K in Q4 2023. 121 funds tracked by Wall St. Rank hold JANX as of Q1 2024.

Old Well Partners reported no remaining Janux Therapeutics position as of Q1 2024 after selling out during the quarter.
Old Well Partners sold 10,300 Janux Therapeutics shares in Q1 2024, an estimated $111K.
Old Well Partners first reported a position in Janux Therapeutics in Q3 2023 and held it in 2 quarters.
Old Well Partners's Janux Therapeutics position peaked at $111K in Q4 2023.
121 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2024.

Based on Old Well Partners's 13F filing for Q1 2024, filed 15 May 2024.